Spearhead Capital Advisors, LLC Corcept Therapeutics Inc Transaction History

Spearhead Capital Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$16.53 - $25.21 $278,960 - $425,443	-16,876 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$17.1 - $23.34 $4,719 - $6,441	276 Added 1.66%	16,876 $334,000
Q3 2021 Oct 27, 2021	SELL	$19.68 - $22.53 $1,810 - $2,072	-92 Reduced 0.55%	16,600 $327,000
Q2 2021 Aug 10, 2021	BUY	$19.97 - $24.43 $49,665 - $60,757	2,487 Added 17.51%	16,692 $367,000
Q1 2021 Apr 28, 2021	SELL	$23.49 - $30.56 $85,574 - $111,330	-3,643 Reduced 20.41%	14,205 $338,000
Q4 2020 Feb 02, 2021	BUY	$16.78 - $27.3 $6,107 - $9,937	364 Added 2.08%	17,848 $467,000
Q3 2020 Oct 16, 2020	BUY	$12.46 - $19.98 $14,291 - $22,917	1,147 Added 7.02%	17,484 $304,000
Q2 2020 Jul 16, 2020	BUY	$11.0 - $18.26 $35,409 - $58,778	3,219 Added 24.54%	16,337 $275,000
Q1 2020 Apr 17, 2020	BUY	$10.11 - $14.04 $132,622 - $184,176	13,118 New	13,118 $156,000

346

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.51B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.